source
- Few European-approved cancer drugs deliver high clinical benefit, analysis showsA new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…
- BMS reports fatal septic pneumonia in MS patient during CAR T trial of zolacabtagene autoleucelBMS disclosed that a participant in its Phase 1 Breakfree-2 study of the CAR T cell therapy zolacabtagene autoleucel died from septic pneumonia. The patient, who had highly active relapsing multip…